55results about How to "Specific diagnosis" patented technology

The invention relates to the immunoassay medical field, concretely, the invention provides a determination kit of the front S area of the large protein (HBV-LP) of hepatitis B virus surface antigen, and a preparation method thereof. The kit based on the invention comprises: 1) a working calibrator of the front S area of the HBV-LP; 2) a streptavidin carrier; 3) a biotinylation monoclonal antibody of the front S area of the HBV-LP; 4) an alkaline phosphatase-marked monoclonal antibody of the front S area of the HBV-LP; and 5) a chemical luminescent substrate. Further, the preparation method of the kit based on the invention comprises the steps of: 1) preparing the working calibrator by the sterling product of the front S area of the HBV-LP; 2) enveloping the carrier by the streptavidin; 3) carrying out biotinylation to the monoclonal antibody of the front S area of the HBV-LP; 4) marking the monoclonal antibody of the front S area of the HBV-LP by the alkaline phosphatase; 5) preparing the chemical luminescent substrate; 6) subpackaging the working calibrator, an enzyme marker and the chemical luminescent substrate; and 7) assembling and installing for forming finished goods. The kit has the advantages of being simple and convenient, fast, sensitive, stable and the like.

The invention discloses a YAP1 gene which can be used as a molecular marker for early diagnosis of Alzheimer's disease. The QPCR (quantitative polymerase chain reaction) experiment proves that compared with common people, the YAP1 gene expression in the blood of an Alzheimer's disease patient is obviously enhanced. The RNA (ribonucleic acid) interfering experiment proves that the YAP1 can influence the Abeta mediated neurotoxicity action. According to the research results, a drug capable of inhibiting YAP1 gene expression or inhibiting YAP1 gene expression product functions can be developed, thereby implementing clinical prevention and treatment of Alzheimer's disease.

The invention discloses NFIC gene capable of serving as a molecular marker for early diagnosis of pituitary adenomas. Experiments of the invention prove that NFIC gene has significantly improved expression in pituitary adenomas tissues when compared to normal pituitary tissues; RNA interference experiments prove that NFIC can affect the proliferation of pituitary adenomas cells. According to the study results of the invention, it is possible to develop drugs capable of inhibiting NFIC gene expression, thus preventing and treating pituitary adenomas clinically.

The invention discloses application of a non-coding RNA relevant to occurrence and development of laryngeal squamous cell carcinoma. The non-coding RNA is LOC100507599. According to the application, through combination of a high throughput sequencing technology with bioinformation analysis, it is found for the first time that expression of the LOC100507599 in a patient suffering from the laryngealsquamous cell carcinoma is up-regulated, and the conclusion is verified through further QPCR, which indicates that the LOC100507599 can serve as a molecular target to be applied to diagnosis and treatment of the laryngeal squamous cell carcinoma.

The invention provides application of a colorectal cancer diagnosis molecular marker, namely, a JAM3 gene which is good in specificity and sensitivity in preparing a colorectal cancer diagnosis kit, and the colorectal cancer diagnosis kit. The application has the main benefits that a novel molecular marker of colorectal cancer is discovered, application of the JAM3 gene to preparation of the colorectal cancer diagnosis kit and the colorectal cancer diagnosis kit are provided, and compared with a conventional detection method, the molecular marker is relatively timely and specific in diagnosis, so that the five-year survival rate of patients suffering from colorectal cancer can be increased, the death rate is reduced, and wide application prospects can be achieved.

The invention discloses a multiple PCR detection kit which can be used in the diagnosis of the swine esophagostomiasis. The detection kit comprises DNA lysis solution, PCR reaction solution, as well as the DNA positive control of toothed Oesophagostomum and the positive control of four-ratched Oesophagostomum. By using the ITS repeat DNA fragments of swine toothed Oesophagostomum and four-ratched Oesophagostomum as genetic markers, the invention builds up a fast, specific and sensitive multiple PCR methods which can be used for diagnosing swine esophagostomiasis. With simple and programmed operation and objective result judgments, the invention can be used for diagnosing swine esophagostomiasis, for investigating epidemiology, and for identifying and diagnosing toothed Oesophagostomum and four-ratched Oesophagostomum.

The invention discloses a molecular marker for diagnosing and treating hysteromyoma. QPCR and Western blot methods prove remarkable difference of expressions of SYBU genes in the hysteromyoma tissue and normal tissues. Moreover, in-vitro cell culture experiments of the invention prove that the expression of the SYBU genes can inhibit the proliferation of hysteromyoma cells while promoting apoptosis, so that the SYBU genes and expression products thereof can be used for preparing a medicine for treating hysteromyoma and are widely and clinically applied.

The invention discloses an MAEA gene and an application of an expression product of the MAEA gene to preparation of a diagnostic product. The diagnostic product can be used for diagnosing myocardial infarction. The risk of myocardial infarction of a testee in the future can be judged or the state of myocardial infarction is confirmed by detecting the level of the MAEA gene and the expression product thereof. The diagnostic product takes peripheral blood of the testee as a detection object, and can achieve noninvasive, rapid, sensitive and accurate diagnostic effects.

The invention belongs to the field of animal disease diagnosis, and particularly relates to a marker GP50 for coenuriasis, as well as a coenuriasis diagnosing kit for diagnosing coenuriasis. According to a coenuriasis indirect ELISA diagnosing method, the sensibility reaches 95%, and the specificity reaches 92.6%. Monitoring of a serum antibody of a goat artificially infected with taenia multiceps discovers that the GP50 antibody values in the whole detection period after infection are all positive. Therefore, the GP50 recombinant protein can be used as the coenuriasis marker, and is used for diagnosing coenuriasis. According to the coenuriasis indirect ELISA diagnosing kit, the coenuriasis can be quickly, sensitively and specifically used for diagnosing coenuriasis, and a foundation is laid for early diagnosis and the treatment effect evaluation of coenuriasis infection.

The invention provides a chemiluminescence immune assay determination kit adopting a human apolipoprotein B100 (ApoB100) monoclonal antibody and a preparation method thereof. The invention also provides the human ApoB100 monoclonal antibody which can specifically recognize human ApoB100, a hybrid tumor for producing the human ApoB100 monoclonal antibody, and a method for high-sensitivity detection of human ApoB100 by the human ApoB100 monoclonal antibody. The chemiluminescence immune assay determination kit has high sensitivity, a wide detection scope and a low cost and is convenient for operation.

The present invention provides a cocktail antigen for bovine tuberculosis allergic reaction detection, comprising ESAT6 antigen, CFP10 antigen, FixB antigen and HSPX antigen; wherein, the mass ratio of ESAT6 antigen, CFP10 antigen, FixB antigen and HSP antigen is 2:2 :1.5:1.5. The cocktail antigen provided by the invention can be used to prepare the detection antigen for bovine tuberculosis allergic reaction. The cocktail antigen of the present invention can replace bovine-type PPD and poultry-type PPD used in comparative allergy, and the effect of comparative allergy can be achieved by using the cocktail antigen for a single intradermal allergy. , After 72 hours, return to the field again to measure the skin thickness, calculate the skin thickness difference and other series of operations, simplified into a single point operation without calculation, the whole detection process is more convenient. At the same time, non-specific mycobacterial infections such as mycobacterium avium can be excluded, and bovine tuberculosis can be diagnosed more specifically.